Cross-Sector entity

Zilong Qiu

Person
9

clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Gene-editing therapy, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Zilong Qiu, all published on July 26, 2026.

1 verified story tracked

Last mentioned: Jul 26, 2026

Entity pulse

Recent coverage · Zilong Qiu

1 story
9 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Zilong Qiu

clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Gene-editing therapy, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Zilong Qiu, all published on July 26, 2026. Each carries 2 original sources on average.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Zilong Qiu. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. University investigation launched

    Shanghai Jiao Tong University School of Medicine announces a special working group to investigate and promises 'serious action'.

  2. Investigative report published

    Science and Retraction Watch publish a joint exposé revealing the death and lack of disclosure, triggering international scrutiny.

  3. Mei receives gene-editing therapy

    Six-year-old girl with rare cognitive delay condition receives spinal infusion of trillions of engineered viruses in an experimental trial.

Stories mentioning Zilong Qiu 1

Biotech clinical trial Strongly negative 9

Gene-Editing Death Rocks Biotech: Trillion-Virus Trial Under Investigation

The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments.

2 sources

Source: channelnewsasia.com · straitstimes.com